Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06205134
Other study ID # NP-006-Epinephrine
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date August 22, 2023
Est. completion date February 5, 2024

Study information

Verified date March 2024
Source Nasus Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults


Description:

An open-label trial in 12 healthy adults. FMXIN002 (3.6 mg and 4.0 mg) will be administered intranasally to healthy adults and compared to IM (0.3mg, EpiPen) by Epinephrine pharmacokinetics, pharmacodynamic response and clinical safety. (https://my.health.gov.il/CliniTrials/Pages/MOH_2023-07-01_012776.aspx.)


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date February 5, 2024
Est. primary completion date February 2, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - 1) Non-smoking, male and female subjects from 18 to 55 years of age. 2) BMI =18 < 30 kg/m2. 3) Females may be of childbearing or non-childbearing potential: - Childbearing potential: o Physically capable of becoming pregnant, must be willing to use acceptable effective methods of contraception - Non-childbearing potential: - Surgically sterile - Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause). 4) Able to tolerate venipuncture. 5) Be informed of the nature of the study and give written consent prior to any study procedure. 6) Willing and being able to remain in the clinic for the entire duration of the confinement period. 7) Have good intravenous access on both arms and hands. Exclusion Criteria: - 1) Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, ischemic heart disease or Arteriosclerosis or cardiovascular disease, autoimmune disease, or Raynaud Phenomenon and any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. 1. Known history or presence of hypersensitivity or idiosyncratic reaction to epinephrine, sulfite, other excipients of epinephrine auto-injector, or any other drug substances with similar activity. 2. Known history or presence of clinically significant lactose, galactose, or fructose allergy 3. Known history or presence of any food allergy. 4. Presence of nostril or septum piercing. 5. Presence of abnormal nasal anatomy (e.g., polyps, unilateral or bilateral abnormalities of the nares, nasal turbinates, or septum including deviated septum). 6. History of nasal surgery. 7. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption other than oral contraceptives. 8. History of drug or alcohol addiction requiring treatment or positive alcohol breath test at check-in. 9. Any acute illness (e.g. cold, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration. 10. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. 11. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine. 12. Inability to communicate well with the Investigators and staff 13. Non-cooperative or unwilling to sign consent form or unwilling to attend scheduled clinic visits and/or comply with the study protocol. 14. Use of tobacco or nicotine-containing products within 6 months prior to drug administration. 15. Females who: - Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to drug administration; - Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration; - Are pregnant (Urine hCG consistent with pregnancy); or - Are lactating. 16. Donation or loss of whole blood (including clinical trials): - =50 mL and <500 mL within 30 days prior to drug administration; - =500 mL within 56 days prior to drug administration. 17. Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results. 18. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet). 19. Have had a tattoo or body piercing within 30 days prior to drug administration. 20. Have clinically significant findings in vital signs measurements at screening. 21. Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic blood pressure decrease in value by more than 10 mmHg, from supine or sitting to standing position during orthostatic blood pressure measurement taken at screening. 22. Have clinically significant findings in a 12-lead ECG. 23. Have clinically significant abnormal laboratory values and hemoglobin <135 g/L for males or <120 g/L for females at screening. 24. Have significant diseases at screening. 25. Have clinically significant findings from a physical examination. 26. Use of the following drugs within 14 days prior to drug administration: - Alpha-adrenergic blocking drugs (e.g., phentolamine); - Anti-arrhythmics; - Beta-adrenergic blocking drugs (e.g., propranolol); - Cardiac glycosides; - Diuretics; - Drugs having effect on cytochrome P450 (CYP450); - Enzyme-altering drugs (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine, etc.); - Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism; - Ergot alkaloids; - Levothyroxine sodium; - Monoamine oxidase inhibitors; - Oral or topical corticosteroids; - Phenylephrine; - Reserpine-type or clonidine-type antihypertensives; - Sodium cromoglycate; or - Tricyclic antidepressants. 27. Use of the following drugs within 7 days prior to drug administration: - Nasal decongestants; - Nonsteroidal anti-inflammatory drugs (NSAIDs); or - Oral or topical antihistamines.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
A: Epinephrine injection
Autoinjector for intramuscular, single-use, 0.3mg
B: FMXIN002 3.6mg
Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
C: FMXIN002 4.0mg
Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril

Locations

Country Name City State
Israel Clinical Pharmacology Unit, Hadassah Medical Center, Ein Karem Jerusalem

Sponsors (4)

Lead Sponsor Collaborator
Nasus Pharma Hadassah Medical Organization, Medistat Ltd., Israel, Pharma Medica Research, Inc.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioavailability of Epinephrine Plasma level of Epinephrine -1 to 2 hours post dose
Primary Blood pressure Pharmacodynamic response -1 to 4 hours post dose
Primary Heart rate Pharmacodynamic response -1 to 4 hours post dose
Primary Respiratory rate Pharmacodynamic response -1 to 4 hours post dose
Secondary 12-lead electrocardiogram Safety -2 up to 1 hour post dose
Secondary Adverse events Safety through study completion, an average of 3 weeks
Secondary Nasal Mucosa health status Nasal cavity examination by physician, recorded on a severity scale
Nasal and Non-Nasal Questionnaire of symptomes, completed by the subjects, using a severity scale.
-1 hour until end of each dosing day, an average 3 weeks.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04475003 - Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Completed NCT00047918 - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing N/A
Active, not recruiting NCT03953482 - Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
Recruiting NCT05112367 - Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
Completed NCT03366298 - Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers Phase 4
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT04696822 - Bioavailability of Nasal Epinephrine Phase 1
Completed NCT03942692 - What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
Completed NCT02854969 - Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device N/A
Completed NCT03282929 - Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD) Phase 1
Recruiting NCT01326741 - Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis N/A
Recruiting NCT06445374 - Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges Phase 1
Completed NCT01217138 - Make up for the Epinephrine Autoinjector Phase 4
Completed NCT02424136 - PEAnut Anaphylaxis Predictors N/A
Completed NCT01432522 - A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine N/A
Completed NCT02028065 - A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) Phase 1
Active, not recruiting NCT01247415 - Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine N/A
Completed NCT00868842 - Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis N/A